Description
Research Areas
- Braincell signalling
- Memory-related pathways
- BDNF research
- Neuronal communication
- Neurotrophic signalling
- Central nervous system research
- ACTH-derived research peptide
- Supplier COA available
- Lot-specific documentation
- Lyophilized research material
Technical Specifications
| Specification | Value |
|---|---|
| Product | Semax |
| Classification | ACTH-derived synthetic peptide |
| Sequence | MEHFPGP |
| CAS | 80714-61-0 |
| Molecular Weight | ~813.9 g/mol |
| Form | Lyophilized powder |
| Intended Use | Laboratory research |
Literature
What researchers are studying
Semax research has focused on how the peptide may affect BDNF, TrkB signalling, synaptic plasticity, memory-related processes, and neuronal communication. Much of the mechanistic work comes from animal and cell studies.
Selected Literature
- Semax and BDNF protein levels — PubMed View PubMed publication
- Semax, BDNF, and TrkB expression — PubMed View PubMed publication
COA Documentation
Analytical values shown are based on the supplier-provided lot-specific COA. Independent Canadian laboratory confirmation has not been completed for this trial lot.
Frequently Asked Questions
Key information about Semax, neurotrophic research, documentation, and intended use.
Semax is a short synthetic peptide used in research on brain signalling and neurotrophic pathways.
A major area of research interest is how Semax may influence BDNF, TrkB signalling, and other proteins involved in nerve-cell communication, synaptic plasticity, and adaptability.
Much of the detailed mechanistic research on Semax comes from animal, cell, and other laboratory models.
Yes. The supplier-provided Certificate of Analysis for the applicable current lot can be linked in the COA Documentation section.
No. This product is intended for laboratory research purposes only and is not intended for human use.







Reviews